Multiple sclerosis trial focusing on people who can’t walk begins recruitment
A new trial focusing solely on multiple sclerosis patients who can’t walk is set to begin recruiting participants.
The ChariotMS, which will be funded by government, charity and commercial backers, will enrol MS patients who are reliant on a wheelchair.
The trial funders include the Efficacy and Mechanism Evaluation Programme, which is a partnership between the Medical Research Council and National Institute for Health Research, as well as the MS Society, the National MS Society USA, Barts Charity, and Merck Serono.
It will study the efficacy of Mavenclad (cladribine) tablets – which are already licensed for highly active relapsing MS – in advanced MS patients who can’t walk. It will seek to determine whether this treatment can slow the rate of upper limb disability progression in people with advanced MS.
Read more: http://www.pharmatimes.com/news/multiple_sclerosis_trial_focusing_on_people_who_cant_walk_begins_recruitment_1357342
The ChariotMS, which will be funded by government, charity and commercial backers, will enrol MS patients who are reliant on a wheelchair.
The trial funders include the Efficacy and Mechanism Evaluation Programme, which is a partnership between the Medical Research Council and National Institute for Health Research, as well as the MS Society, the National MS Society USA, Barts Charity, and Merck Serono.
It will study the efficacy of Mavenclad (cladribine) tablets – which are already licensed for highly active relapsing MS – in advanced MS patients who can’t walk. It will seek to determine whether this treatment can slow the rate of upper limb disability progression in people with advanced MS.
Read more: http://www.pharmatimes.com/news/multiple_sclerosis_trial_focusing_on_people_who_cant_walk_begins_recruitment_1357342
